Federated Hermes’s AgomAb Therapeutics NV AGMB Stock Holding History
Bought
Maintained
Sold
Other funds holding AGMB
SL
Federated Hermes's AGMB Position: Q3 2026 in Review
Federated Hermes reduced its AgomAb Therapeutics NV (AGMB) stake by 0.25% in Q3 2026, selling an estimated $51.6K and leaving 1,614,014 shares worth $17.9M. The position accounts for 0.03% of the portfolio, ranked #514.
Federated Hermes first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. The position peaked at $21M in Q2 2026. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.
- Federated Hermes held 1,614,014 shares of AgomAb Therapeutics NV worth $17.9M as of Q3 2026.
- Federated Hermes sold 3,986 AgomAb Therapeutics NV shares in Q3 2026, an estimated $51.6K.
- AgomAb Therapeutics NV made up 0.03% of Federated Hermes's portfolio in Q3 2026, its #514 holding.
- Federated Hermes first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
- Federated Hermes's AgomAb Therapeutics NV position peaked at $21M in Q2 2026.
- 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.
Based on Federated Hermes's 13F filing for Q3 2026, filed 12 Nov 2026.